CoChat

Cell death-based treatment of lung adenocarcinoma

Open access

The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.

Abstract

The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of all lung cancer cases. In spite of achievements in understanding the pathogenesis of this disease and the development of new approaches in its treatment, unfortunately, lung ADC is still one of the most aggressive and rapidly fatal tumor types with overall survival less than 5 years. Lung ADC is often diagnosed at advanced stages involving disseminated metastatic tumors. This is particularly important for the successful development of new approaches in cancer therapy. The high resistance of lung ADC to conventional radiotherapies and chemotherapies represents a major challenge for treatment effectiveness. Here we discuss recent advances in understanding the molecular pathways driving tumor progression and related targeted therapies in lung ADCs. In addition, the cell death mechanisms induced by different treatment strategies and their contribution to therapy resistance are analyzed. The focus is on approaches to overcoming drug resistance in order to improve future treatment decisions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-017-0063-y

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The EGFR-TKI resistance mechanisms and related targeted therapies in lung ADC The resistance to the EGFR-TKI involves activation of several pathways. One of the mechanisms depends on the appearance of secondary mutations in EGFR, such as Thr790Met, L858R or deletion of exon 19. Another one includes activations of bypass signaling pathways such as PI3CA, MET, ERK, HER2 or AXL. Low mRNA level or polymorphism of pro-apoptotic protein Bim could also mediate intrinsic resistance of lung ADC to EGFR inhibitors. Alternatively, autophagy stimulation might sustain resistance to the RTK inhibitors (erlotinib and gefitinib) in these tumors. The inhibition of autophagy with chloroquine could accelerate RTKI-induced apoptosis and overcome resistance of lung ADC cells. For more detail, see the text
Fig. 1 The EGFR-TKI resistance mechanisms and related targeted therapies in lung ADC The resistance to the EGFR-TKI involves activation of several pathways. One of the mechanisms depends on the appearance of secondary mutations in EGFR, such as Thr790Met, L858R or deletion of exon 19. Another one includes activations of bypass signaling pathways such as PI3CA, MET, ERK, HER2 or AXL. Low mRNA level or polymorphism of pro-apoptotic protein Bim could also mediate intrinsic resistance of lung ADC to EGFR inhibitors. Alternatively, autophagy stimulation might sustain resistance to the RTK inhibitors (erlotinib and gefitinib) in these tumors. The inhibition of autophagy with chloroquine could accelerate RTKI-induced apoptosis and overcome resistance of lung ADC cells. For more detail, see the textCC BY · PubMed Central
Fig. 2 Link between the immune system state and response of immune checkpoint molecule inhibitors: CTLA-4 inhibitors (ipilimumab and tremelimumab), PD-1 inhibitors (pembrolizumab and nivolumab), PD-L1 inhibitors (atezolizumab and durvalumab) For more detail, see the text
Fig. 2 Link between the immune system state and response of immune checkpoint molecule inhibitors: CTLA-4 inhibitors (ipilimumab and tremelimumab), PD-1 inhibitors (pembrolizumab and nivolumab), PD-L1 inhibitors (atezolizumab and durvalumab) For more detail, see the textCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 160 references

Research works printed but not linked: 2

  1. Gumerlock, P., Pryde, B. J. & Kimura, T. Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma. Proc. Am. Soc. Clin. Oncol. 22, 662 (2003). (abstr 2661).
  2. Reck, M., von Pawel, J. & Zatlouka, P. et al. First-line Bevacizumab combined with Cisplatin/Gencitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC): AVAIL (BO17704), a phase III randomized study. J. Thorac. Oncol. 12, 1487–1488 (2008).

Cited by

See all 834

Metadata

Authors
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B.
Affiliations
Lomonosov Moscow State University (RU)
Corresponding author
Zhivotovsky, Boris
Venue
Cell Death & Disease
Published
2018-01-25
Volume
9
Issue
2
Pages
117-117
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2789011876
Cited by
768
References
159
Citations by year
2026: 38 · 2025: 97 · 2024: 131 · 2023: 137 · 2022: 160 · 2021: 118 · 2020: 57 · 2019: 19 · 2018: 10
FWCI
5.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Vetenskapsrådet (521-2014-2258)
  • Barncancerfonden (PR2016-0090)
  • Russian Science Foundation (14-25-00056)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
lung adenocarcinoma, cell death, drug resistance, targeted therapy, molecular pathways, tumor progression, chemoresistance, radiotherapy resistance, metastatic lung cancer
MeSH terms
Adenocarcinoma of Lung, Humans, Immunotherapy, Models, Biological, Mutation, Apoptosis, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cell death-based treatment of lung adenocarcinoma. https://app.cochat.ai/papers/10.1038/s41419-017-0063-y
The paper
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018). Cell death-based treatment of lung adenocarcinoma. Cell Death & Disease. https://doi.org/10.1038/s41419-017-0063-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.